How to Build a Deal Model That Beats PE on Price
M&A Science
Buyers who mistake a high LOI bid for a winning strategy are easy prey for sellers who know the growth equity playbook. Jeremy Segal's position: precision at the LOI stage is a stronger differentiator than price. Jeremy Segal is EVP of Corporate Development at Progress (NASDAQ: PRGS), a publicly traded software company that has nearly doubled revenue through M&A, from under $400 million to nearly $1 billion. He has closed roughly 50 acquisitions across his career at Progress, LogMeIn, and Akamai. How do you build a cost-optimization model before LOI for lines you know you can execute?...
info_outline
The People You Lose in M&A: Key Talent Retention Before Close
M&A Science
The people who leave post-close are usually the ones the deal depended on. Which means the problem starts with how you read culture before LOI and whether financial incentives are the only retention tool you are building with. Haseeb Jawad heads corporate development at Commvault, running a lean team with full accountability from sourcing through integration. He has led two to three acquisitions per year across multiple companies, sat on both sides of a transaction, and serves as his own IMO lead. The signals that tell you a deal will lose people are visible from the first founder...
info_outline
How to Buy Companies That Aren't Profitable Yet
M&A Science
Venture-backed companies are priced at their future state, not their current revenue. When growth stalls and another fundraising round stops making sense, the gap between VC valuation and what a strategic buyer will pay becomes the hardest conversation in any deal process. Matt Arsenault, VP of Corporate Development & Strategic Alliances at Jamf, has run this play across hundreds of targets. His work starts before the deal does, with the founder relationship, the cap table, and a clear-eyed conversation about risk tolerance that most corp dev teams never have. What You'll Learn ...
info_outline
When Deals Get Weird: Stories You Don't See in the CIM
M&A Science
, , , , , , , and Eight deal professionals share the M&A moments that never make the CIM. A birthday cake in a management presentation that confirmed a culture fit and influenced a bid. A buyer who died before close, forcing a nine-month restart from scratch. Eight years of customer revenue data on a 1980s IBM that management claimed did not exist. A target quietly heading toward Chapter 11 while diligence was underway. Unexpected events mid-deal are not exceptions. They are the deal. How you read them is what separates experienced practitioners from everyone else. What You'll Learn:...
info_outline
The Real Work Behind the Close: When Judgment Beats the Checklist
M&A Science
, , , , and Winning a banker-run auction at 5% under the highest bid. Closing a deal when co-sellers have not spoken in months. Getting through 22 countries of employment complexity with a client who refused to work with EOR providers. Acquiring a Netherlands-based public company and discovering the due diligence documents were in Dutch. These are the problems that no playbook prepares you for. Four corp dev professionals share how they handled them, and what it cost when they got it wrong. What You'll Learn How to win a competitive auction when you’re not the highest bidder What...
info_outline
The Nordic Compounder Playbook: How Jörgen Wigh Runs 85 Companies With 22 HQ Staff and No Integration
M&A Science
Lagercrantz Group has completed 90+ acquisitions over 20 years and never sold one. CEO Jörgen Wigh runs 85 niche B2B companies under a 22-person headquarters with no integration, no exits, and no value realization targets. This is Part 2 of 2. , while Part 2 is the operating culture. Jörgen gets into how 85 autonomous companies are governed without a matrix structure, why this model exists almost exclusively in the Nordics, what makes a founder walk away from a signed deal twice, why Lagercrantz deliberately targets a 10% failure rate, and what he would do differently starting from scratch...
info_outline
The Nordic Compounder Playbook: How Lagercrantz Bought 90 Companies and Never Sold One
M&A Science
Jörgen Wigh has been CEO of Lagercrantz Group (STO: LAGR-B) for over 20 years. In that time he completed 90+ acquisitions, built a portfolio of 85 niche B2B companies, and delivered 15 consecutive years of record earnings per share. No capital raises. No forced integration. No exits. The Nordic compounder model has quietly outperformed global markets for decades, and Lagercrantz is one of the longest-running, most disciplined examples of it in operation. In Part 1 of 2, Jörgen walks through the deal model behind that track record. What You'll Learn How Lagercrantz finds...
info_outline
M&A Integration Technology: What Actually Works
M&A Science
| | | Four integration leaders from Intel, Coursera, Ansys, and UKG debate what integration technology actually delivers versus what creates expensive overhead and where the real value leaks are. Todd Manley, Jim Buckley, Carey Pugh, and Mahesh Ganesan bring decades of deal experience to a conversation with no presentations and no curated answers. What You'll Learn Why the diligence-to-integration handoff keeps failing and what actually fixes it How to evaluate integration technology without getting sold on complexity Where AI is genuinely useful in integration today and where it is not...
info_outline
Partner Before You Buy: The Pre-Acquisition Strategy Corp Dev Teams Skip
M&A Science
Corp dev teams treat M&A and partnerships as separate tracks, but Tomer Stavitsky looks at them holistically. In this episode, he breaks down the partner-first approach: an acquisition framework for situations where the target isn't ready, the PE owner isn't selling, or your integration capacity isn't there. He walks us through structuring the partnership, keeping the acquisition thesis alive through execution, negotiating and defending a right of first refusal, and managing the three-way stakeholder dynamic without signaling the wrong things at the wrong time. What You'll Learn ...
info_outline
How M&A Turns a Chemical Company Into a Tech Business
M&A Science
Chandradev Mehta, SVP Strategy and Business Development at Hexion Inc., breaks down how a commodity chemical company uses M&A to transform into a technology-enabled, chemistry-as-a-service business. He covers the acquisition of an AI and MarTech company, the build vs. buy vs. partner decision framework, integration planning discipline, banker selection, small deal execution, and JV governance. What You'll Learn How to build a genuine build vs. buy vs. partner framework and when each is right Why buying a commercialized or near-commercialized business changes your risk profile in...
info_outlineRodrigo Dominguez Sotomayor, Partner at White & Case LLP
Most US buyers approach Latin America M&A the same way they do a domestic deal — optimize the process, close fast, move on. That approach gets deals killed.
Rodrigo Dominguez Sotomayor, Partner at White & Case LLP, has spent 25 years closing transactions across every major Latin America market. In this episode, he walks through what actually determines outcomes: antitrust consent timelines, labor regimes that make post-close restructuring expensive, and the relationship dynamics that can unwind a billion-dollar deal a week before signing.
What You’ll Learn In This Episode:
- How a PE fund lost a billion-dollar deal over 2% — and why it was avoidable
- Why LatAm antitrust approvals can take up to nine months and how to plan around them
- What no employment-at-will actually costs you post-close
- Why showing up to a LatAm auction without reps & warranties insurance is a disadvantage
- How to negotiate with family founders when price isn't what closes the deal
- Why 80% of Latin America deals now run through auctions
Your standard diligence process will miss things that kill LatAm deals — statutory severance you didn't model, title searches that go back a hundred years, antitrust consent timelines that block close for months, auctions where R&W insurance is already expected.
Running diligence on a LatAm target right now? The M&A Science Hub has two resources built directly from this episode — the LATAM Diligence Delta Checklist and the Latin America M&A Entry Playbook — plus an AI tutor trained on 400+ practitioner conversations you can pressure-test your current deal against.
Members get access before the episode goes public. → Access inside the Intelligence Hub — members only.
____________________
This episode is sponsored by DealRoom
Stop juggling six different tools to run one deal. DealRoom brings pipeline management, diligence tracking, document sharing, and team collaboration into one platform. Purpose-built for M&A teams who need to move fast without losing control. request your demo today: https://hubs.ly/Q03ZMvQX0
____________________
Episode Chapters
[00:04:26] Rodrigo's background: 25 years across Latin America M&A
[00:06:57] How a cross-border acquisition actually starts
[00:10:17] Bilateral deals and family-owned businesses
[00:12:52] Reading the room: when not to push on numbers
[00:14:12] The billion-dollar deal that fell apart over 2%
[00:20:02] Antitrust consent regimes across LatAm
[00:29:49] The union leader story
[00:27:14] Labor, employment, and statutory severance
[00:34:04] Reps & warranties insurance: now standard in LatAm
[00:38:44] Auction vs. bilateral: the 80/20 split
[00:44:01] FinTech opportunity in Latin America
[00:48:05] NVCA forms and deal documentation
[00:52:48] Post-close integration: what actually determines success
[00:55:51] Craziest Thing in M&A